SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2009 / Cilt: 39 - Sayı: 6

Kronik hepatit C’li hastalarda karaciğer fibrozisinin saptanmasında AST seviyesi, protrombin zamanı, ve trombosit sayısının belirleyici rolü

The predictive role of AST level, prothrombin time, and platelet count in the detection of liver fibrosis in patients with chronic hepatitis C

Bahar TAŞDELEN
Güliz SARAÇOĞLU
Özlem KANDEMİR
Gürbüz POLAT
Pages
857–862
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The relationship between the platelet count

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We aimed to assess the predictive value of a combination some of basic serum biochemical markers for the diagnosis of clinically significant fibrosis in chronic hepatitis C.Materials and Methods: Blood samples from 68 patients with chronic hepatitis C infection were analyzed for aspartate aminotransferase, prothrombin INR, and platelet count.
📊
Key Findings & Data:The relationship between the serum biochemical markers and severity of the stages were examined.Results: A strong association was found between the fibrosis stage and platelet count and GUCI (P < 0.001, P = 0.035 respectively) but not APRI ([AST/ULN] / Platelet count [ ×109 /L]) × 100) (P = 0.052).
💡
Conclusion & Impact:The relationship between the platelet count
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: We aimed to assess the predictive value of a combination some of basic serum biochemical markers for the diagnosis of clinically significant fibrosis in chronic hepatitis C.Materials and Methods: Blood samples from 68 patients with chronic hepatitis C infection were analyzed for aspartate aminotransferase, prothrombin INR, and platelet count. The liver histopathology was evaluated using the Knodell protocol. The relationship between the serum biochemical markers and severity of the stages were examined.Results: A strong association was found between the fibrosis stage and platelet count and GUCI (P < 0.001, P = 0.035 respectively) but not APRI ([AST/ULN] / Platelet count [ ×109 /L]) × 100) (P = 0.052). The relationship between the platelet count

Özet

Amaç: Kronik hepatit C’de bazı temel serum biyokimyasal testlerinin şiddetli fibrozisi tanımlamada doğruluk derecelerini değelendirmeyi amaçladık. Yöntem ve gereç: Kronik hepatit C enfeksiyonlu 68 hastadan kan örnekleri aspartat minotransferaz, protrombin zamanı ve trombosit sayısı için analiz edildi. Karaciğer histopatolojisi Knodell protokolü kullanılarak değerlendirildi. Serum biyokimyasal belirleyicileri ve stage şiddeti arasındaki ilişki araştırıldı.Bulgular: Fibrozis derecesi ile trombosit sayısı ve GUCI arasındaki ilişki anlamlı bulundu (P < 0,001, P = 0,035, sırayla), ancak APRI ile ([AST/ULN] / Trombosit sayısı [×109 /L]) × 100) (P = 0.052) anlamlı bulunmadı. Trombosit sayısının

🔖

Cite This Article

TAŞDELEN, B., SARAÇOĞLU, G., KANDEMİR, Ö., POLAT, G. (2022). Kronik hepatit C’li hastalarda karaciğer fibrozisinin saptanmasında AST seviyesi, protrombin zamanı, ve trombosit sayısının belirleyici rolü. Turkish Journal of Medical Sciences, Cilt: 39 - Sayı: 6, 857–862. https://ajindex.com/articles/611696

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase to- platelet ratio index for the prediction of hepatitis C-related ibrosis: A systematic review. Hepatology 2007; 46: 912-19
  2. Hepatitis C –global prevalence (update). Wkly Epidemiol Rec 2000; 12: 3682-94
  3. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005; 25: 72-83
  4. Hadziyannis SJ, SetteH Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140: 346-55
  5. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z et al. Impact of pegylated interferonalpha 2b and ribavirin on liver ibrosis in patients with chronic hepatitis C, Gastroenterology 2002; 122: 1303-13
  6. Friedman LS. Controversies in liver biopsy; who, where, when, how, why? Curr Gastroenterol Rep 2004; 6: 30-36
  7. Bedossa P, Dargere D Paradis V. Sampling variability of liver ibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57
  8. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F et al. Transient elastography: a new noninvasive method for assessment of hepatic ibrosis. Ultrasound Med Biol 2003; 29: 1705-13
  9. Sebestiani G, Alberti A. Non invasive ibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94
  10. Rockey DC, Bissell DM. Noninvasive measures of liver ibrosis. Hepatology 2006; 43 (2 Suppl 1): 113-20
  11. Lackner C, Struber G, Lieg B, Leibl S, Ofner P, Bankuti C et al. Comparision and validation of simple noninvasive tests foprediction of ibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82
  12. Westin J, Ydrborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM et al. A non-invasive ibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol 2008; 43: 73-80
  13. Desmet VJ, Gerber M, Hoofnahgle JH, Manns M, Scheuer P. Classiication of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513–1520
  14. Ono E, Shiratori Y, Okudaira T. Platelet count relects stage of chronic hepatitis C. Hepatol Res 1999; 15: 192-200
  15. Phol A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of ibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-46
  16. Karasu Z, Tekin